Table 5.

Correlations between the accuracy of sentinel lymph node biopsy (identification and false-negative rates) and clinicopathological factors in breast cancer patients after neodjuvant chemotherapy

Clinicopathological factors	Identification rate (43/51)		False-negative rate (6/31)
	n (%)	P	n (%)	P
Age
≥50	22/27 (81.5%)	0.838	4/20 (20%)	1.000
<50	21/24 (87.5%)		2/11 (18.2%)
Method of lymphatic mapping
Blue dye only	5/8 (62.5%)	0.073	0/2	0.753
Radioactive colloid only	5/7 (71.4%)		1/4 (25%)
Both	33/36 (82.1%)		5/25 (20%)
Location of radiocolloid injection
Subareolar	12/17 (70.6%)	0.134	2/8 (25%)	0.634
Peritumoral	31/34 (91.7%)		4/23 (17.4%)
Operator
Chief physician	26/29 (89.7%)	0.432	4/19 (21.1%)	0.836
Associate Chief Physician	12/16 (75.0%)		1/8 (12.5%)
Other	5/6 (83.3%)		1/4 (25%)
Tumor localization
Upper outer	16/19 (84.2%)	0.992	3/13 (23.1%)	0.905
Central	10/12 (83.3%)		1/6 (16.7%)
Other	17/20 (85.0%)		2/12 (16.7%)
Histological type
Invasive ductal carcinoma	32/39 (82.1%)	0.653	5/23 (21.7%)	0.744
Invasive lobular carcinoma	8/9 (88.9%)		1/6 (16.7%)
Composite carcinoma	3/3 (100%)		0/2
Tumor classification
T1-2	29/32 (90.1%)	0.226	2/20 (10%)	0.151
T3-4	14/19 (73.7%)		4/11 (41.7%)
Clinical nodal status before treatment
N1	26/28 (92.9%)	0.143	1/18 (5.9%)	0.059
N2-3	17/23 (73.9%)		5/13 (35.8%)
Pathologic tumor response
Grade 1–2	12/16 (75%)	0.450	4/11 (36.4%)	0.175
Grade 3–4	21/24 (87.5%)		2/16 (12.5%)
Grade 5	10/11 (90.9%)		0/4
Pathologic response in lymph node
N-B	5/7 (71.4%)	0.470	2/5 (40%)	0.241
N-C	26/31 (83.9%)		4/26 (15.4%)
N-D	12/13 (92.3%)		—